Faruqi & Faruqi Highlights Class Action Against PepGen with Deadline Approaching in 2025

Investigation into PepGen Class Action



Faruqi & Faruqi, LLP, a prominent national securities law firm, has initiated an inquiry into potential claims involving PepGen Inc. (NASDAQ: PEPG). The firm invites investors who experienced losses by purchasing PepGen securities between March 7, 2024, and March 3, 2025, to explore their legal options. This comes amid a federal securities class action lawsuit filed against the company.

As the deadline for seeking the role of lead plaintiff in this lawsuit looms closer on August 11, 2025, affected shareholders are being urged to take action. Investors can reach out directly to Josh Wilson, a partner at Faruqi & Faruqi, for guidance. He can be contacted at either 877-247-4292 or 212-983-9330, extension 1310.

The basis of the allegations against PepGen centers around claims that company executives made false and misleading statements about the company's product, PGN-EDO51. Claims include that the drug was less effective and posed more risks than previously communicated. Furthermore, the firm's lead plaintiff, representing the largest financial interest in relief sought by the class, has been identified.

The Details of the Case


The complaint items revolve around a series of press releases and statements made by PepGen that misled investors about the potential of its product. For instance, on July 30, 2024, PepGen announced 'positive clinical data' from its ongoing CONNECT1 study. However, subsequent evaluations by financial analysts suggested that the observed increase in dystrophin levels (a protein pertinent to muscle function) fell short of expectations, leading to a stock price decline of over 32%.

In mid-December 2024, PepGen faced another setback when it received a clinical hold notice from the FDA, highlighting concerns that resulted in a further drop in share price. In January 2025, additional warnings prompted more significant price declines amid serious safety concerns associated with ongoing studies. Finally, in May 2025, PepGen declared that it would halt development of its DMD programs after concluding PGN-EDO51 did not meet its target levels, causing further investor panic.

As shareholders watch events unfold, the role of the lead plaintiff potentially becomes crucial. Defined as the investor with the largest financial stake in the case, this individual will oversee the litigation process on behalf of the affected group. Nonetheless, participation as a lead plaintiff is not obligatory for all investors, and the ability to claim recovery remains irrespective of this decision.

What Affected Investors Should Do


Faruqi & Faruqi encourage anyone with any insights regarding PepGen's operations, including whistleblowers or former employees, to reach out to the firm for further discussion. This class action presents a critical opportunity for investors to seek accountability from the corporation for the alleged mismanagement and failure to disclose essential risks.

For more information on the ongoing class action or to seek legal advice, visit Faruqi & Faruqi’s website or contact the firm directly. Stay informed about developments related to this case by following updates on social platforms like LinkedIn and X, or Facebook.

In the world of corporate and securities law, similar cases underscore the importance of transparency and accuracy in communications with investors. As the details of PepGen's situation continue to evolve, the focus remains on the potential ramifications for both the company and its stakeholders.

Topics Financial Services & Investing)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.